Drug Profile

VG 301

Alternative Names: RAGe™; VG-301

Latest Information Update: 23 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Virogin Biotech
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Interleukin 15 receptor alpha expression stimulants; Interleukin-12 expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Solid tumours

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

08 Feb 2023 Pharmacodynamics data from preclinical studies in Solid tumors released by Virogin Biotech
07 Jul 2022 Preclinical trials in Solid tumours in Canada (Intratumoural) (Virogin Biotech pipeline, July 2022)
02 Jun 2020 VG 301 is available for licensing as of 02 Jun 2020. https://virogin.com/partnering

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com